logo
Plus   Neg
Share
Email

Nektar Publishes Two Manuscripts On Its Immuno-oncology Candidate, Bempeg

Nektar Therapeutics (NKTR), a biopharmaceutical company, published preclinical data on its lead immuno-oncology candidate, NKTR-214, bempegaldesleukin (bempeg), an investigational CD122-preferential interleukin-2 pathway agonist designed to provide activation and proliferation of cancer-killing immune cells. The company said the data showed that bempeg, in combination with immune-based therapies including checkpoint inhibition, antigen-specific vaccination and adoptive cell transfer therapy, enhanced T-cell mediated tumor control.

Bempeg in combination with checkpoint inhibitors and other immune-mediating agents is being evaluated in clinical trials, Nektar Therapeutics noted.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Twitter could face a fine of up to $250 million from the U.S. Federal Trade Commission regarding its use of phone numbers and email addresses to target advertisements. Lord & Taylor joined the growing list of U.S. retailers who filed for bankruptcy amid the coronavirus pandemic. Lord & Taylor, one of the oldest department store chains in the U.S., filed for bankruptcy protection in the Eastern Court of Virginia on Sunday. The company operated 38 stores that have remained temporarily closed since March this year due to the pandemic. Thomson International Inc. is recalling Red, Yellow, White, and Sweet Yellow Onions for potential contamination with Salmonella, according to a statement by the U.S. Food and Drug Administration or FDA. The onions are in distribution since May 1, 2020. They were sold to wholesalers, restaurants, and retail stores in all 50 U.S. states, the District of Columbia and Canada.
RELATED NEWS
Follow RTT